Differential Pathophysiological Roles of Centrum Semiovale Perivascular Spaces in Cerebral Amyloid Angiopathy and Deep Perforator Arteriopathy: A Biomarker Synthesis
Posted inClinical Updates Neurology news

Differential Pathophysiological Roles of Centrum Semiovale Perivascular Spaces in Cerebral Amyloid Angiopathy and Deep Perforator Arteriopathy: A Biomarker Synthesis

This review synthesizes evidence distinguishing perivascular space enlargement mechanisms in cerebral amyloid angiopathy (CAA) versus deep perforator arteriopathy (DPA), highlighting the diagnostic utility of CSF Aβ42/40 ratios in vascular amyloid pathology.
Patient-Centered Outcomes in Geriatric Oncology: Analyzing the Influence of Survival vs. Quality of Life Preferences in the GAP70+ Trial
Posted inClinical Updates news Oncology

Patient-Centered Outcomes in Geriatric Oncology: Analyzing the Influence of Survival vs. Quality of Life Preferences in the GAP70+ Trial

A secondary analysis of the GAP70+ trial reveals that while 71.7% of older adults with advanced cancer prioritize quality of life, their clinical outcomes—including survival and toxicity—remain unchanged compared to those prioritizing survival, suggesting a systemic lack of responsiveness to patient goals.
Long-term Efficacy and Safety of Bimekizumab in Moderate-to-Severe Hidradenitis Suppurativa: A 2-Year Synthesis of the BE HEARD Clinical Program
Posted inClinical Updates Dermatology news

Long-term Efficacy and Safety of Bimekizumab in Moderate-to-Severe Hidradenitis Suppurativa: A 2-Year Synthesis of the BE HEARD Clinical Program

This review synthesizes 2-year results from the BE HEARD phase 3 trials and their extension, demonstrating that dual IL-17A/F inhibition with bimekizumab provides deep, durable clinical responses and a favorable safety profile for patients with moderate-to-severe hidradenitis suppurativa.